Entacapone
Entacapone is a catechol-O-methyl transferase inhibitor which is licensed for treatment of Parkinson's disease as an adjunct to L-dopa.
Entacapone is effective in reducing "on-off" fluctuations and may improve dyskinesias by permitting a reduction in the dose of L-dopa.
- wearing-off is one of the most frequent problems encountered by levodopa-treated patients
- entacapone, a peripheral inhibitor of catechol-O-methyltransferase (COMT), reduces this motor complication by prolonging the effect of levodopa.
Unwanted effects include:
- dyskinesias, which usually resolve when the L-dopa dose is reduced (often by 10-30%)
- diarrhoea which is often temporary
- discolouration of urine
Reference:
- Brooks DJ, Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74: 1071-1079.
- MeReC Bulletin (1999), 10 (10), 37-40.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.